148 related articles for article (PubMed ID: 21883836)
1. Hormone therapy for prostate cancer and the risk of stroke: a 5-year follow-up study.
Chung SD; Chen YK; Wu FJ; Lin HC
BJU Int; 2012 Apr; 109(7):1001-5. PubMed ID: 21883836
[TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
3. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
4. No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer: a 5-year follow-up study.
Kao LT; Lin HC; Chung SD; Huang CY
Asian J Androl; 2017; 19(4):414-417. PubMed ID: 27232853
[TBL] [Abstract][Full Text] [Related]
5. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer.
Lage MJ; Barber BL; Markus RA
Urology; 2007 Dec; 70(6):1104-8. PubMed ID: 18158027
[TBL] [Abstract][Full Text] [Related]
6. No increased risk of coronary heart disease for patients receiving androgen deprivation therapy for prostate cancer in Chinese/Taiwanese men.
Wang LH; Liu CK; Chen CH; Kao LT; Lin HC; Huang CY
Andrology; 2016 Jan; 4(1):128-32. PubMed ID: 26711703
[TBL] [Abstract][Full Text] [Related]
7. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation therapy did not increase the risk of Alzheimer's and Parkinson's disease in patients with prostate cancer.
Chung SD; Lin HC; Tsai MC; Kao LT; Huang CY; Chen KC
Andrology; 2016 May; 4(3):481-5. PubMed ID: 27062333
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
[TBL] [Abstract][Full Text] [Related]
10. Increased Fall Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer.
Wu FJ; Sheu SY; Lin HC; Chung SD
Urology; 2016 Sep; 95():145-50. PubMed ID: 27318262
[TBL] [Abstract][Full Text] [Related]
11. Decline of the red blood cell count in patients receiving androgen deprivation therapy for localized prostate cancer: impact of ADT on insulin-like growth factor-1 and erythropoiesis.
Hara N; Nishiyama T; Takizawa I; Saito T; Kitamura Y; Takahashi K
Urology; 2010 Jun; 75(6):1441-5. PubMed ID: 20110105
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
Saigal CS; Gore JL; Krupski TL; Hanley J; Schonlau M; Litwin MS;
Cancer; 2007 Oct; 110(7):1493-500. PubMed ID: 17657815
[TBL] [Abstract][Full Text] [Related]
13. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
[TBL] [Abstract][Full Text] [Related]
14. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
15. Risk of acute myocardial infarction after androgen-deprivation therapy for prostate cancer in a Chinese population.
Teoh JY; Chan SY; Chiu PK; Poon DM; Cheung HY; Hou SS; Ng CF
BJU Int; 2015 Sep; 116(3):382-7. PubMed ID: 25327618
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
18. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy.
Berruti A; Bollito E; Cracco CM; Volante M; Ciccone G; Porpiglia F; Papotti M; Scarpa RM; Dogliotti L
Prostate; 2010 May; 70(7):718-26. PubMed ID: 20087896
[TBL] [Abstract][Full Text] [Related]
19. Functional heterogeneity of prostatic intraepithelial neoplasia: the duration of hormonal therapy influences the response.
Kang TY; Nichols P; Skinner E; Groshen S; Valin G; Ye W; Raghavan D
BJU Int; 2007 May; 99(5):1024-7. PubMed ID: 17244277
[TBL] [Abstract][Full Text] [Related]
20. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
